Apex Labs

Based in Canada, Apex Labs is a pharmaceutical company focused on transforming mental health care through the development and deployment of psilocybin-based treatments. The company focuses on creating formulations that allow for take-home use under physician oversight, tailored particularly for conditions like anxiety, depression, PTSD, and suicidality. 

As of May 2024, Apex Labs was evaluating two drug assets: 

1) A micro-dose drug candidate (APEX-52) for take-home dosage aimed at mild to moderate disease severity 

2) A macro-dose drug candidate (APEX-90) positioned for in-clinic dosage coupled with psychotherapy for more severe cases.

The company’s operations and clinical trials are conducted in Canada, leveraging the supportive regulatory environment to advance its research and development efforts. 

Key customers and partnerships

Apex Labs’ primary target audience comprises veterans and first responders suffering from anxiety, depression, and PTSD.

The company collaborates closely with research institutions and clinical experts, and with entities like Centricity Research to manage complex clinical trials. These collaborations are pivotal for conducting large-scale studies and enhancing the credibility and reach of its psilocybin treatments.

Funding and Financials

In February 2022, Apex Labs raised USD 4 million in a Series A funding round. The intended use of the funds was undisclosed. At the time of the funding, the company was valued at a pre-money valuation of USD 12 million.